Evista (raloxifene), the new "designer estrogen"

    You're going to hear a lot about Evista (raloxifene), the new "designer estrogen" from Lilly.

    It's INITIALLY approved to prevent osteoporosis.

    But Evista and future designer estrogens will revolutionize hormone replacement therapy because they're more selective. They mimic the effects of estrogen in SOME tissues...but not others.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote